Pivotal trials of CAR T cells for B cell malignancies
| Characteristic . | Target . | Costimulatory domain . | Patient group . | No. (evaluable) . | CR rate (%) . | FDA approved? . | Reference . |
|---|---|---|---|---|---|---|---|
| ALL | |||||||
| Penn/CHOP phase 1/2a | CD19 | 41BB | Children | 60 | 93 | Yes | 12 |
| ELIANA phase 2 (tisagenlecleucel) | CD19 | 41BB | Children | 75 | 81 | Yes | 11 |
| MSKCC phase 1 | CD19 | CD28 | Children | 25 | 75 | No | 35 |
| Seattle phase 1/2 | CD19 | 41BB | Children | 43 | 93 | No | 36 |
| NCI phase 1 | CD19 | CD28 | Children | 51 | 61 | No | 37 |
| MSKCC phase 1 | CD19 | CD28 | Adults | 53 | 83 | No | 38 |
| Penn phase 1 | CD19 | 41BB | Adults | 20 | 90 | No | 39 |
| NCI phase 1 | CD22 | 41BB | Children | 15 | 73 | No | 40 |
| Penn/CHOP phase 1 | CD22 | 41BB | Adults and children | 8 | 50 | No | 41 |
| Non-Hodgkin lymphoma | |||||||
| Tisagenlecleucel | CD19 | 41BB | Adults | 93 | 40 | Yes | 13 |
| Axicabtagene ciloleucel | CD19 | CD28 | Adults | 101 | 54 | Yes | 14, 15 |
| Lisocabtagene maraleucel | CD19 | 41BB | Adults | 256 | 53 | Yes | 23 |
| Brexucabtagene autoleucel | CD19 | CD28 | Adults | 60 | 62 | Yes | 17 |
| Multiple myeloma | |||||||
| Idecabtagene vicleucel | BCMA | 41BB | Adults | 128 | 33 | Yes | 18 |
| Chronic lymphocytic leukemia | |||||||
| Penn phase 2 | CD19 | 41BB | Adults | 24 | 25 | No | 42 |
| Characteristic . | Target . | Costimulatory domain . | Patient group . | No. (evaluable) . | CR rate (%) . | FDA approved? . | Reference . |
|---|---|---|---|---|---|---|---|
| ALL | |||||||
| Penn/CHOP phase 1/2a | CD19 | 41BB | Children | 60 | 93 | Yes | 12 |
| ELIANA phase 2 (tisagenlecleucel) | CD19 | 41BB | Children | 75 | 81 | Yes | 11 |
| MSKCC phase 1 | CD19 | CD28 | Children | 25 | 75 | No | 35 |
| Seattle phase 1/2 | CD19 | 41BB | Children | 43 | 93 | No | 36 |
| NCI phase 1 | CD19 | CD28 | Children | 51 | 61 | No | 37 |
| MSKCC phase 1 | CD19 | CD28 | Adults | 53 | 83 | No | 38 |
| Penn phase 1 | CD19 | 41BB | Adults | 20 | 90 | No | 39 |
| NCI phase 1 | CD22 | 41BB | Children | 15 | 73 | No | 40 |
| Penn/CHOP phase 1 | CD22 | 41BB | Adults and children | 8 | 50 | No | 41 |
| Non-Hodgkin lymphoma | |||||||
| Tisagenlecleucel | CD19 | 41BB | Adults | 93 | 40 | Yes | 13 |
| Axicabtagene ciloleucel | CD19 | CD28 | Adults | 101 | 54 | Yes | 14, 15 |
| Lisocabtagene maraleucel | CD19 | 41BB | Adults | 256 | 53 | Yes | 23 |
| Brexucabtagene autoleucel | CD19 | CD28 | Adults | 60 | 62 | Yes | 17 |
| Multiple myeloma | |||||||
| Idecabtagene vicleucel | BCMA | 41BB | Adults | 128 | 33 | Yes | 18 |
| Chronic lymphocytic leukemia | |||||||
| Penn phase 2 | CD19 | 41BB | Adults | 24 | 25 | No | 42 |
Trials identified by location and/or eventual commercial product name.
CHOP, Children's Hospital of Philadelphia; MSKCC, Memorial Sloan Kettering Cancer Center; NCI, National Cancer Institute; Penn, University of Pennsylvania; Seattle, Seattle Children's Hospital.